台灣代理商-BRAND/AGENCY/代理品牌/APExBIO台灣代理商

APExBIO提供優質的胜肽和生物分析試劑，廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域， 還提供定制的服務，包括多肽合成，抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析，高效液相色譜，質譜，和HMNR數據。

 

 

表觀遺傳學(Epigenetics)是基因表達的可遺傳修飾(heritable modifications)，與 DNA 序列(DNA sequence)的變化無關。表觀遺傳修飾(Epigenetic modifications)主要發生在 DNA 或組蛋白八聚體(histone octamer)上。有幾種類型的表觀遺傳學修飾(epigenetics modifications)，DNA-甲基轉移酶 (DNMT) 的 DNA 甲基化和組蛋白的共價修飾，例如乙醯化(acetylation)、甲基化(methylation)、磷酸化(phosphorylation)和泛素化(ubiquitination)。組蛋白乙醯轉移酶 (HAT) 的組蛋白乙醯化參與轉錄激活，而組蛋白去乙醯化酶 (HDAC) 的組蛋白去乙醯化與轉錄抑制(transcriptional repression)有關。組蛋白去甲基化(Histone demethylation)與賴氨酸特異性去甲基化酶 (lysine-specific demethylase , LSD) 和含有組蛋白去甲基化酶 (JHDM) 的 JmjC 結構域(JmjC domain)有關。

核小體(nucleosome)由四種組蛋白（H2A、H2B、H3 和 H4）組成，它們是染色質(chromatin)的主要組成部分。特定化學基團的添加和去除稱為表觀遺傳標記(epigenetic marks)，它調節染色質結構並影響基因表達。此外，RNA 與抑制性染色質狀態(repressive chromatin state)的形成密切相關。

表觀遺傳(Epigenetic)機制在細胞水平上響應環境變化，從而影響細胞可塑性(plasticity)。染色質(Chromatin)和表觀遺傳調控(epigenetic regulation)在發育和應激反應期間的基因組編程中發揮重要作用，表觀遺傳學缺陷(defects in epigenetics)可導致癌症(cancer)、炎症(inflammation)和代謝紊亂(metabolic disorders)等。MG 149 是一種組蛋白乙酰轉移酶 (HAT) 抑製劑，對 Tip60 和 MOF 的 IC50 值分別為 74μM 和 47μM [1]。

MG 149  (Tip60 HAT inhibitor) 選擇性抑制劑 | CAS# 1243583-85-8 APExBIO貨號 B3276

MG 149 是漆樹酸衍生物(anacardic acid derivative)。它顯示對 MYST 類型的 HAT(histone acetyltransferases)：Tip60 和 MOF 的選擇性抑制(selective inhibition)，IC50 值分別為 74μM 和 47μM。對接研究表明，MG 149 對 Tip60 的抑制作用相對於 Tip60 的 Ac-CoA 結合口袋中的 Ac-CoA 具有競爭性。 MG 149 還使用生物素化組蛋白 H3 或組蛋白 H4 肽作為底物抑制 HeLa 細胞核提取物中 HAT 的活性。與組蛋白 H4 相比，它被發現對組蛋白 H3 更有效。此外，DNA 微陣列(DNA microarrays) , 顯示 MG149 抑制 p53 和 NF-kB 通路以及數量非常有限的其他通路 [1, 2]。

• 1. Zichong Li. “Functional characterization of transcription elongation machinery in HIV transcription and latency.” University of California. 2019.
• 2. Li Z, Mbonye U, et al. “The KAT5-Acetyl-Histone4-Brd4 axis silences HIV-1 transcription and promotes viral latency.” PLoS Pathog. 2018 Apr 23;14(4):e1007012. PMID:29684085

Storage	Store at RT
M.Wt	340.46
Cas No.	1243583-85-8
Formula	C22H28O3
Solubility	≥114 mg/mL in DMSO; ≥30.5 mg/mL in EtOH; insoluble in H2O
Chemical Name	2-(4-heptylphenethyl)-6-hydroxybenzoic acid
SDF	Download SDF
Canonical SMILES	CCCCCCCC1=CC=C(CCC2=C(C(O)=O)C(O)=CC=C2)C=C1
Shipping Condition	Ship with blue ice, or upon other requests.
General tips	For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon.

4′-bromo-Resveratrol (Sirt1 和 Sirt3 抑制劑) | CAS# 1224713-90-9 APExBIO貨號 C3552

4′-bromo-Resveratrol 是一種 Sirt1 和 Sirt3 抑制劑。Sirtuins 是調節衰老過程(aging processes)和許多生理功能的蛋白質脫乙醯酶(protein deacetylases)。白藜蘆醇可激活人類 Sirt1 並抑制 Sirt3，並可以模擬卡路里限制效應(mimic calorie restriction)，包括在低等生物中延長壽命。體外(In vitro)：在先前的研究中使用 4′-溴白藜蘆醇(4’-bromo-Resveratrol)研究了去乙酰化酶調節。  4′-溴白藜蘆醇(4’-bromo-Resveratrol)抑制 Sirt3 的效力比白藜蘆醇高得多，而且它還抑制而不是激活 Sirt1。人 Sirt3/4′-溴白藜蘆醇肽複合物的晶體結構確定了兩個結合位點。內部位點引起了有效的抑制作用。  4′-溴白藜蘆醇(4’-bromo-Resveratrol)干擾 NAD+ 和底物肽的結合，並將其溴-苯基基團延伸到無法識別的位點口袋中。發現  4′-溴白藜蘆醇(4’-bromo-Resveratrol)的第二個結合位點位於 Sirt3 的表面，並通過兩個螺旋連接到肽結合活性位點環。在 Sirt1 中，該位點似乎包含一個對其被小分子激活至關重要的殘基，因此4′-溴白藜蘆醇(4’-bromo-Resveratrol)構成了長期尋找的變構 Sirt1 激活劑結合位點的候選者(candidate) [1]。體內(In vivo)：到目前為止，還沒有 4′-溴白藜蘆醇(4’-bromo-Resveratrol)的動物體內數據。臨床試驗：截至目前，4′-溴白藜蘆醇(4’-bromo-Resveratrol)仍處於臨床前開發階段(preclinical development stage)。

• 1. Wang LJ, Lee YC, et al. “Non-mitotic effect of albendazole triggers apoptosis of human leukemia cells via SIRT3/ROS/p38 MAPK/TTP axis-mediated TNF-α upregulation.” Biochem Pharmacol. 2018 Nov 7. pii: S0006-2952(18)30472-6. PMID:30414389

Physical Appearance	A crystalline solid
Storage	Store at -20°C
M.Wt	291.1
Cas No.	1224713-90-9
Formula	C14H11BrO2
Solubility	≤50mg/ml in ethanol;50mg/ml in DMSO;100mg/ml in dimethyl formamide
Chemical Name	5-[(1E)-2-(4-bromophenyl)ethenyl]-1,3-benzenediol
SDF	Download SDF
Canonical SMILES	OC1=CC(O)=CC(/C=C/C2=CC=C(Br)C=C2)=C1
Shipping Condition	Ship with blue ice, or upon other requests.
General tips	For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon.

MS023 (type I PRMTs inhibitor抑制劑) | CAS# 1831110-54-3APExBIO貨號 B6183

MS023 is a type I PRMTs inhibitor.Protein arginine methyltransferases (PRMTs) play a critical role in various biological processes. PRMT overexpression has been observed in a variety of human diseases including cancer. PRMTs has been divided into three categories: type I PRMTs for catalyzing mono- and asymmetric dimethylation of arginine residues, type II PRMTs for catalyzing mono- and symmetric dimethylation of arginine residues, and type III PRMT for catalyzing only monomethylation of arginine residues.

MS023 是一種 I 型 PRMTs 抑制劑。蛋白質精氨酸甲基轉移酶 (inhibitor.Protein arginine methyltransferases ,PRMT) 在各種生物過程中發揮著關鍵作用。已在包括癌症(cancer)在內的多種人類疾病中觀察到 PRMT 過度表達(overexpression)。 PRMTs分為三類：I型PRMTs用於催化精氨酸殘基(arginine residues)的單甲基化和不對稱二甲基化，II型PRMTs用於催化精氨酸殘基(arginine residues)的單甲基化和對稱二甲基化(symmetric demethylation)，III型PRMTs僅催化精氨酸殘基的單甲基化(monomethylation)。體外(In vitro)：先前的研究表明，MS023 對 I 型 PRMT 具有出色的效力，但對 II 型和 III 型 PRMT、蛋白質賴氨酸甲基轉移酶(protein lysine methyltransferases)以及 DNA 甲基轉移酶(DNA methyltransferases)均完全無活性。此外，PRMT6 與 MS023 的晶體結構表明 MS023 與底物結合位點結合。此外，MS023 可以有效降低組蛋白精氨酸不對稱二甲基化的細胞水平。此外，MS023 可以降低精氨酸不對稱二甲基化的水平，同時還可以增加精氨酸單甲基化和對稱二甲基化的細胞水平 [1]。體內：到目前為止，還沒有動物體內數據報導。臨床試驗：截至目前，MS023仍處於臨床前開發階段。

• 1. Pyun JH, Kim HJ, et al. “Cardiac specific PRMT1 ablation causes heart failure through CaMKII dysregulation.” Nat Commun. 2018 Nov 30;9(1):5107. PMID:30504773

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	287.4
Cas No.	1831110-54-3
Formula	C17H25N3O
Solubility	≥28.7 mg/mL in DMSO; ≥13.7 mg/mL in EtOH; ≥23.3 mg/mL in H2O
Chemical Name	N1-((4-(4-isopropoxyphenyl)-1H-pyrrol-3-yl)methyl)-N1-methylethane-1,2-diamine
SDF	Download SDF
Canonical SMILES	NCCN(C)CC1=CNC=C1C2=CC=C(OC(C)C)C=C2
Shipping Condition	Ship with blue ice, or upon other requests.
General tips	For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon.

 

品項	CAS#	#貨號	應用
Romidepsin (FK228, depsipeptide)	CAS#128517-07-7	貨號A8173	HDAC1/HDAC2，強效和選擇性抑制劑
Pirarubicin	CAS#72496-41-4	貨號B2295	anthracycline anti-neoplastic doxorubicin
Tunicamycin	CAS# 15663-27-1	貨號A8321	高效、廣譜的化療藥物
Azithromycin	CAS#83905-01-5	貨號A2213	Hsp90 inhibitor
Bleomycin Sulfate	CAS# 9041-93-4	貨號B1398	Antibiotic by inhibiting protein synthesis
Nystatin (Fungicidin)	CAS#1400-61-9	貨號B1993	antifungal antibiotic
Rapamycin	CAS#53123-88-9	貨號A8167	Original antifungal antibiotic
Daptomycin	CAS#103060-53-3	貨號A1206	Calcium-dependent antibiotic

品項	CAS#	#貨號	應用
MG 149  (Tip60 HAT inhibitor) 選擇性抑制劑	CAS# 1243583-85-8	貨號 B3276	HAT inhibitor
4′-bromo-Resveratrol	CAS# 1224713-90-9	貨號 C3552	Sirt1 和 Sirt3 抑制劑
MS023	CAS# 1831110-54-3	貨號 B6183	type I PRMTs inhibitor抑制劑
CHZ868	N/O	貨號B5980	Type II JAK2 inhibitor
Chidamide	CAS#743420-02-2	貨號B5916	Novel HDAC inhibitor
RGFP966	CAS#1357389-11-7/1396841-57-8	貨號A8803	Specific HDAC3 inhibitor
EPZ-6438	CAS#1403254-99-8	貨號A8221	EZH2 inhibitor, potent and selective
Bromodomain Inhibitor, (+)-JQ1	CAS# 1268524-70-4	貨號A1910	BET bromodomain inhibitor

 

Catalog No.	Name	CAS	Purity	Short Summary
A1001	Adrenomedullin (1-12), human		98.99%	Vasodilator
A1002	Beta-Amyloid (1-11)	190436-05-6	98.58%	Amyloidogenic peptide
A1003	Amyloid β-Protein (1-15)	183745-81-5	98.58%	Principal component of amyloid
A1004	Amyloid Precursor C-Terminal Peptide		92.28%	For beta amyloid generation
A1005	Beta-Sheet Breaker Peptide iAβ5	182912-74-9	98.17%	Peptide which can inhibit amyloidogenesis
A1006	Angiotensin I (human, mouse, rat)	484-42-4	98.99%	Precursor of angiotensin II
A1007	Angiotensin 1/2 (1-9)	34273-12-6	98.77%	Vasoconstrictor
A1008	Anti-Inflammatory Peptide 1	118850-71-8	99.99%	PLA2 inhibitor
A1009	ANP (1-11), rat		95.92%	Vasodilator
A1010	Myelopeptide-2 (MP-2)		98.98%	Peptide used for restoring human T lymphocytes
A1011	b-Casomorphin (1-3)	72122-59-9	99.56%	Milk protein casein analog, have an opioid effect
A1012	Dynorphin (2-17), amide, porcine		99.94%	A modulator of pain response
A1013	Endomorphin-1	189388-22-5	98.79%	Agonist of μopioid receptors,highly potent and selective
A1014	Beta-Lipotropin (1-10), porcine	77875-68-4	99.17%	Morphine-like substance
A1015	alpha-Endorphin	59004-96-5	98.00%	Neurotransmitters
A1016	Ac-Endothelin-1 (16-21), human		98.49%	ETA/ETB agonist,vasoconstrictor
A1018	Platelet Membrane Glycoprotein IIB Peptide (296-306)		98.92%	Inhibits platelet aggregation
A1019	Glucagon (19-29), human	64790-15-4	95.54%	Potent Ca2+/Mg2+-ATPase inhibitor
A1020	GnRH Associated Peptide (GAP) (1-13), human	100111-07-7	99.41%	Inhibitor of prolactin secretion
A1021	Epidermal Growth Factor Receptor Peptide (985-996)	96249-43-3	98.41%	EGFR Peptide (985-996)
A1022	GTP-Binding Protein Fragment, G alpha		74.64%	Hydrolyzes GTP to GDP
A1023	Laminin (925-933)	110590-60-8	99.93%	Extracellular matrix glycoprotein
A1024	LEP (116-130) (mouse)	258276-95-8	98.17%	An antiobesity hormone
A1025	a-MSH, amide	581-05-5	99.59%	Melanocyte-stimulating hormones
A1026	β-Interleukin I (163-171), human	106021-96-9	99.58%	T cell activator
A1027	β-Interleukin II (44-56)		99.37%	Cytokine,regulating WBC
A1028	Cadherin Peptide, avian	127650-08-2	99.90%	Role in cell adhesion
A1029	Fas C- Terminal Tripeptide	189109-90-8	97.61%	AC-SER-LEU-VAL-OH
A1030	Interleukin II (60-70)		99.99%	Cytokine,regulating WBC
A1031	Myelin Basic Protein (68-82), guinea pig	98474-59-0	99.06%	Myelin Basic Protein
A1032	Adrenorphin	88377-68-8	97.00%	Endogenous μ/κ opioid agonist,potent and selective
A1033	[Ser25] Protein Kinase C (19-31)	136795-05-6	99.80%	PKC substrate
A1034	Acetyl Angiotensinogen (1-14), porcine	66641-26-7	99.81%	Angiotensinogen precursor
A1035	Papain Inhibitor	70195-20-9	97.15%	Inhibitor of peptidase activity of Papain
A1036	Thrombin Receptor Activator for Peptide 5 (TRAP-5)	141685-53-2	98.07%	Thrombin Receptor Activator for Peptide 5
A1037	TRH Precursor Peptide		98.91%	Thyrotropin Releasing Hormone Precursor Peptide
A1040	Myelin Basic Protein (87-99)	118506-26-6	99.85%	Encephalitogenic peptide
A1041	Angiotensin (1-7)	51833-78-4	99.70%	Vasoconstriction peptide hormone
A1043	Angiotensin III (human, mouse)	13602-53-4	98.97%	Aldosterone stimulator
A1044	Gap 26	197250-15-0	99.56%	Gap junction blocker peptide, mapping to connexin 43 residue 63-75
A1045	Gap 27	198284-64-9	97.64%	Selective gap junction blocker
A1046	Dynamin inhibitory peptide	251634-21-6	99.53%	Peptide inhibitor of GTPase dynamin
A1047	Angiotensin 1/2 (1-5)	58442-64-1	99.65%	Vasoconstrictor
A1048	Angiotensin 1/2 (1-6)	47896-63-9	99.85%	Vasoconstrictor
A1049	Angiotensin 1/2 (5-7)		98.36%	Vasoconstrictor
A1050	Angiotensin 1/2 (2-7)		99.80%	Vasoconstrictor
A1051	alpha-1 antitrypsin fragment		99.10%	Protease inhibitor
A1052	alpha-1 antitrypsin fragment 235-243 [Homo sapiens]/[Papio hamadryas]/[Cercopithecus aethiops]		98.00%	Protease inhibitor
A1053	amyloid A protein fragment [Homo sapiens]		99.77%	Apolipoproteins related to HDL in plasma
A1056	Angiotensin 1/2 + A (2 – 8)	51833-76-2	99.56%	Vasoconstrictor
A1057	coagulation factor II (thrombin) B chain fragment [Homo sapiens]		99.68%	Trypsin-like serine protease
A1058	Prothrombin (474-477) [Mus musculus]		99.61%	Role in coagulation cascade
A1061	Cytochrome c – pigeon (88-104)	86579-06-8	98.58%	Triggers T Cell response
A1062	Cytochrome c fragment (93-108)		99.20%	Initiates apoptosis
A1063	Cytochrome P450 CYP1B1 (190-198) [Homo sapiens]		98.32%	Sequence: H2N-FLDPRPLTV-OH
A1066	erbB-2		99.72%	Tyrosine kinase (TK) receptor
A1067	eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) (387-394) [Multiple species]		98.20%	Elongation factor-1 subunit
A1068	eukaryotic translation initiation factor 3		98.44%	Eukaryotic translation initiator
A1069	ferritin heavy chain fragment [Multiple species]		99.67%	Ferritin heavy chain fragment
A1070	IgG light chain variable region [Homo sapiens]/IgM/kappa antibody [Mus musculus]		99.79%	IgG light chain region
A1071	immunoglobulin light chain variable region fragment [Homo sapiens]		99.82%	Immunoglobulin light chain fragment
A1072	immunoglobulin light chain variable region fragment [Homo sapiens]/[Mus musculus]		97.50%	Immunoglobulin light chain fragment
A1073	Immunoglobulin M heavy chain (IGHM) fragment [Homo sapiens]		99.36%	Immunoglobulin M heavy chain
A1075	Influenza A virus fragment		97.61%	Leu-Lys-Phe-Ala-Phe-Ser-Met-Met
A1077	Lamin fragment		99.57%	Lys-Ala-Gly-Gln-Val-Val-Thr-Ile-Trp
A1078	Large T antigen – rhesus polyomavirus 560-568		99.08%	Large T antigen
A1079	MAP kinase fragment [Multiple species]		97.00%	Lys-Tyr-Ile-His-Ser-Ala-Asn-Val-Leu
A1080	matrix protein (3-15) [Zaire ebolavirus]		98.14%	Viral envelope associated protein peptide
A1081	MHC class II antigen (45-57) [Homo sapiens]		83.75%	Major histocompatibility complex
A1082	ovalbumin (324-338) [Gallus gallus]/[Coturnix coturnix]		98.23%	Triggers immuno response
A1083	p53 tumor suppressor fragment		99.00%	Regulates cell cycle
A1084	parathyroid hormone (7-34) [Homo sapiens]/[Macaca fascicularis]		99.71%	Enhancer of blood calcium level
A1085	prostate apoptosis response protein PAR-4 (2-7) [Homo sapiens]		99.46%	Transcriptional repressor
A1086	Rac GTPase fragment		99.65%	Fragment of small signaling G proteins
A1087	Rhodopsin peptide		99.88%	Pigment in retina photoreceptor cell;GPCR
A1088	Ribosomal protein L3 peptide (202-222) amide		99.76%	HIV-1 TAR RNA-binding protein
A1090	signal transducer and activator of transcription 6 fragment		99.79%	STAT6 transcription factor
A1092	survivin (baculoviral IAP repeat-containing protein 5) (21-28)		98.07%	Cancer Biology Peptides
A1093	transferrin fragment		99.69%	Transferrin fragment
A1094	tumor protein p53 binding protein fragment [Homo sapiens]/[Mus musculus]		99.06%	P53 binding protein fragment
A1096	type II collagen fragment		99.56%	Specific for cartilaginous tissues
A1097	ubiquitin specific protease 3 fragment		96.99%	Deubiquitinates uH2A/uH2B
A1098	vitamin D binding protein precrusor (208-218) [Homo sapiens]/[Oryctolagus cuniculus]		99.83%	vitamin D binding protein precrusor
A1099	vitamin D binding protein precursor (353-363) [Homo sapiens]		99.52%	Highly polymorphic serum glycoprotein
A1105	BNP (1-32), human	114471-18-0	98.00%	Brain natriuretic peptide
A1107	Cdk2/Cyclin Inhibitory Peptide I		99.88%	Cell division protein kinase 2
A1109	Endostatin (84-114)-NH2 (JKC367)		99.66%	Angiogenesis inhibitor
A1111	Endothelin-1 (1-15), amide, human		98.00%	Vasoconstrictor agent
A1112	Nitric Oxide Synthase (599-613) Blocking Peptide, Bovine Endothelial Cell		99.74%	Blocker of NO production
A1114	Parathyroid Hormone (1-34), bovine	12583-68-5	99.84%	Enhancer of blood calcium level
A1115	Peptide YY(3-36), PYY, human	123583-37-9	96.92%	Y2R agonist
A1117	PKA inhibitor fragment (6-22) amide	121932-06-7	98.62%	PKA inhibitor
A1118	S6 Kinase Substrate Peptide 32		98.28%	Measures the activity of kinases that phosphorylate ribosomal protein S6.
A1121	Melanocyte stimulating hormone release inhibiting factor	2002-44-0	98.00%	MSH release-inhibiting factor
A1123	Amyloid Beta-Peptide (12-28) (human)	107015-83-8	99.46%	sequence H2N-VHHQKLVFFAEDVGSNK-OH
A1124	Amyloid Beta-Peptide (1-40) (human)	131438-79-4	98.43%	Amyloid precursor protein
A1129	Parathyroid hormone (1-34) (human)	52232-67-4	99.82%	Increases blood calcium level
A1131	COG 133	514200-66-9	99.03%	ApoE mimetic peptide
A1132	β-Pompilidotoxin	216064-36-7	99.84%	Slows Na+ channel inactivation
A1133	Epidermal growth factor receptor (994-1002) acetyl/amide		98.50%	EGF-family receptor
A1134	Agouti-related Protein (AGRP) (25-82), human		99.67%	Agouti-related peptide(25-82)
A1136	Fusion glycoprotein (92-106) [Human respiratory syncytial virus]		98.42%	glycoprotein
A1138	Glycoprotein B (485-492)		99.61%	Invovled in HSV viral cell entry
A1140	HBcAg [Hepatitis B virus] (18-27)		99.74%	Indicator of active viral replication
A1141	hemagglutinin (332-340) [Influenza A virus]		98.84%	Partial antigenic glycoprotein
A1142	hemagglutinin precursor (114-122) amide [Influenza A virus]		99.70%	Partial antigenic glycoprotein
A1143	heparin cofactor II precursor (SERPIND1) fragment [Homo sapiens]		98.14%	Thrombin inhibitor
A1144	heparin cofactor II precursor fragment [Homo sapiens]		99.72%	Thrombin inhibitor
A1146	Histone-H2A-(107-122)-Ac-OH		97.81%	Histone-H2A peptide
A1147	Luteinizing hormone releasing hormone human acetate salt (LHRH)	33515-09-2	98.34%	acitivator of MMP-2 and MMP-9, selective
A1149	YAP-TEAD Inhibitor 1 (Peptide 17)		99.56%
A1169	10058-F4	403811-55-2	98.03%	C-Myc-Max dimerization inhibitor
A1173	AG-18	118409-57-7	99.68%	EGFR/PDGFR inhibitor
A1174	AMG-517	659730-32-2	96.97%	TRPV1 antagonist,potent and highly selective
A1185	BMS-754807	1001350-96-4	99.53%	IGF-1R/InsR inhibitor,potent and selective
A1186	AMG-208	1002304-34-8	98.00%	C-Met inhibitor,potent and highly selective
A1196	SGX-523	1022150-57-7	99.73%	MET inibitor, highly selective, ATP-competitive
A1198	Levetiracetam	102767-28-2	98.00%	Antiepileptic drug
A1206	Daptomycin	103060-53-3	98.77%	Calcium-dependent antibiotic
A1229	Lansoprazole	103577-45-3	98.00%	H+,K+-ATPase inhibitor
A1266	WYE-354	1062169-56-5	99.39%	MTOR inhibitor,potent,ATP-competitive and cell-permeable
A1267	Adapalene	106685-40-9	99.91%	RARβ and RARγ agonist
A1295	Granisetron HCl	107007-99-8	99.85%	5-HT3 receptor antagonist
A1296	Exemestane	107868-30-4	98.00%	Steroidal aromatase inhibitor,selective and irreversible
A1302	GSK1904529A	1089283-49-7	98.55%	Selective IGF-1R/IR inhibitor
A1307	Letrozole	112809-51-5	99.90%	Non-steroidal aromatase inhibitor
A1313	Gatifloxacin	112811-59-3	99.70%	Fluoroquinolone antibiotic,inhibits bacterial TOPO II
A1334	Mosapride Citrate	112885-42-4	99.90%	5-HT receptor agonist
A1337	U0126-EtOH	1173097-76-1	99.34%	MEK1/2 inhibitor
A1352	Zoledronic Acid	118072-93-8	98.00%	Potent nitrogen-containing bisphosphonates
A1366	Rocuronium Bromide	119302-91-9	98.00%	TGF-βR I kinase inhibitor
A1367	AP26113	1197958-12-5	98.00%	Anaplastic lymphoma kinase (ALK) inhibitor
A1372	AZD3514	1240299-33-5	98.00%	Androgen receptor downregulator
A1373	Biapenem	120410-24-4	98.00%	Highly broad spectrum antibiotic agent
A1379	Nelarabine	121032-29-9	98.44%	Prodrug of ara-G for T-LBL/T-ALL
A1379	Nelarabine	121032-29-9	98.44%	Prodrug of ara-G for T-LBL/T-ALL
A1379	Nelarabine	121032-29-9	98.44%	Prodrug of ara-G for T-LBL/T-ALL
A1379	Nelarabine	121032-29-9	98.44%	Prodrug of ara-G for T-LBL/T-ALL
A1387	AZD5363	1143532-39-1	99.94%	AKT inhibitor,pyrrolopyrimidine derived
A1389	WZ4002	1213269-23-8	98.89%	Mutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent
A1393	WZ8040	1214265-57-2	98.36%	EGFR T790M inhibitor,irreversible amd potent
A1402	Gemcitabine HCl	122111-03-9	99.92%	Inhibits DNA synthesis,deoxycytidine analog
A1404	Rigosertib sodium salt	1225497-78-8	98.79%	Plk1 inhibitor
A1412	Clofarabine	123318-82-1	99.41%	Antimetabolite,inhibit DNA polymerase and ribonucleotide reductase
A1413	CEP-32496	1188910-76-0	98.27%	BRAF(V600E)inhibitor,highly potent
A1425	Losartan Potassium (DuP 753)	124750-99-8	99.87%	Angiotensin AT1 receptor antagonist
A1428	Fulvestrant (ICI 182,780)	129453-61-8	99.18%	Estrogen receptor antagonist, high affinity
A1435	CP-945598 HCl	686347-12-6	98.00%	CB1 antagonist,selective and high affinity
A1447	Cilnidipine	132203-70-4	99.94%	Blocker of Dual L- and N-type calcium channel
A1450	Lidocaine	137-58-6	99.92%	Anasthetic and class Ib antiarrhythmic agent
A1493	ABT-751 (E7010)	141430-65-1	99.38%	Inhibitor of microtubule polymerization,antimitotic
A1500	7-Methoxycoumarin-4-acetyl-P-L-G-L-β-(2,4-dinitrophenylamino)A-R amide	140430-53-1	99.93%	Substrate of matrix metalloproteinases assay
A1501	Mca-Pro-Leu-NH2		98.00%	Substrate of matrix metalloproteinases assay
A1602	Dexrazoxane HCl (ICRF-187, ADR-529)	149003-01-0	99.85%	Topoisomerase II inhibitor,intracellular ion chelator,cardioprotective agent
A1605	Dynasore	304448-55-3	98.00%	Dynamin and GTPase inhibitor
A1606	L-a-Hydroxyglutaric acid disodium salt	63512-50-5	95.00%	salt form of L-α-Hydroxyglutaric acid
A1615	GANT61	500579-04-4	99.50%	GLI antagonist
A1623	Epothilone A	152044-53-6	98.00%	Microtubule stabilizing macrolide
A1624	Zaragozic Acid A	142561-96-4	98.00%	rat liver squalene synthase inhibitor
A1630	Epothilone B (EPO906, Patupilone)	152044-54-7	99.72%	Microtubule stabilizing macrolide
A1632	SB202190 (FHPI)	152121-30-7	99.84%	P38 MAPK inhibitor
A1655	GW2580	870483-87-7	99.69%	CFMS kinase/CSF-1R inhibitor,selective and ATP-competitive
A1659	Dutasteride	164656-23-9	99.46%	5-alpha-reductase inhibitor
A1663	PD98059	167869-21-8	99.25%	MEK inhibitor,selective and reversible
A1664	Celecoxib	169590-42-5	99.71%	Selective cyclooxygenase-2 (COX-2) inhibitor
A1670	Enzastaurin (LY317615)	170364-57-5	98.94%	PKC beta inhibitor,potent and selective
A1684	Aprepitant	170729-80-3	98.62%	Substance P (SP) inhibitor
A1709	GW9508	885101-89-3	99.93%	FFA1/GPR40 agonist,potent and selective
A1718	Posaconazole	171228-49-2	99.47%	Sterol C14ɑ demethylase inhibitor
A1720	Duvelisib (IPI-145, INK1197)	1201438-56-3	99.55%	PI3K-δ/PI3K-γ inhibitor
A1723	Roscovitine (Seliciclib,CYC202)	186692-46-6	99.10%	CDK inhibitor,potent and selective
A1736	PA-824	187235-37-6	99.62%	Anti-tuberculosis drug
A1745	Galanthamine HBr	1953-04-4	98.81%	Acetylcholinesterase inhibitor
A1748	Ramelteon	196597-26-9	99.89%	Agonist of melatonin receptor(M1-M2),highly selective
A1755	Tenofovir Disoproxil Fumarate	202138-50-9	98.61%	Antiretroviral agent( HIV-1 RT inhibitor)
A1765	Vincristine sulfate	2068-78-2	98.64%	Microtubule disrupter,antitumor agent
A1767	Entecavir Hydrate	209216-23-9	99.67%	Antiviral drug used in hepatitis B infection
A1769	KU-0060648	881375-00-4	98.00%	Dual DNA-PK/PI3-K inhibitor, ATP-competitive
A1778	Vatalanib (PTK787) 2HCl	212141-51-0	99.95%	Tyrosine kinase receptor inhibitor
A1792	PD184352 (CI-1040)	212631-79-3	99.41%	Selective MEK inhibitor
A1794	LY2835219	1231930-82-7	98.48%	CDK4/6 inhibitor,potent and selective
A1796	Mianserin HCl	21535-47-7	99.42%	5-HT2 receptor antagonist
A1821	Ki8751	228559-41-9	99.43%	VEGFR-2 inhibitor,potent and selective
A1832	Doxorubicin (Adriamycin) HCl	25316-40-9	99.64%	Antitumour antibiotic,inhibits TOPO II.
A1835	Pelitinib (EKB-569)	257933-82-7	98.49%	EGFR inhibitor,potent and irreversible
A1845	Canertinib (CI-1033)	267243-28-7	99.52%	HER family tyrosine kinase inhibitor
A1855	Bumetanide	28395-03-1	98.77%	NKCC cotransporter inhibitor
A1882	Cediranib (AZD217)	288383-20-0	99.82%	VEGFR inhibitor receptor,highly potent
A1888	TRAM-34	289905-88-0	98.00%	KCa3.1 blocker,potent and highly selective
A1894	SL-327	305350-87-2	99.80%	Selective MEK1/2 inhibitor
A1900	PSI	158442-41-2	97.64%	Proteasome inhibitor
A1901	Q-VD-OPh hydrate	1135695-98-5	98.32%	Cell-permeable, irreversible pan-caspase inhibitor
A1902	Z-VAD-FMK	187389-52-2	98.60%	Cell-permeable, irreversible pan-caspase inhibitor
A1903	E 64d	88321-09-9	98.14%	Cysteine protease inhibitor
A1904	Boc-D-FMK	187389-53-3,634911-80-1	98.00%	Pan-caspase inhibitor
A1905	3-Deazaneplanocin,DZNep	102052-95-9	98.00%	S-adenosylhomocysteine and EZH2 inhibitor
A1906	Decitabine (NSC127716, 5AZA-CdR)	2353-33-5	99.77%	Deoxycytidine analog and cellular diifferentiation inducer
A1907	5-Azacytidine	320-67-2	98.00%	DNA methyltransferase inhibitor.
A1908	AMI-1	20324-87-2	99.49%	PRMT1 inhibitor
A1909	BIX 01294	935693-62-2	98.38%	G9a and GLP inhibitor
A1910	Bromodomain Inhibitor, (+)-JQ1	1268524-70-4	98.98%	BET bromodomain inhibitor
A1912	Lomeguatrib	192441-08-0	99.55%	MGMT inhibitor
A1913	RG 108	48208-26-0	99.86%	DNA methyltransferase inhibitor
A1914	UNC0638	1255580-76-7	98.66%	G9a/GLP HMTase inhibitor, potent and selective
A1915	Zebularine	3690-10-6	99.18%	DNA methylation inhibitor
A1920	Z-DEVD-FMK	210344-95-9	98.00%	Caspase-3 inhibitor
A1921	Z-DQMD-FMK	767287-99-0	98.00%	Caspase-3 inhibitor,cell-permeable
A1922	Z-VDVAD-FMK	210344-92-6	98.00%	Caspase-2 inhibitor
A1923	Z-VEID-FMK		98.41%	Caspase-6 inhibitor
A1924	Z-WEHD-FMK	210345-00-9	98.00%	Caspase 5 inhibitor,potent,cell-permeable and irreversible
A1925	Caspase-3/7 Inhibitor I	220509-74-0	99.31%	Caspase-3/7 inhibitor
A1926	CA 074	134448-10-5	98.07%	Cathepsin B inhibitor
A1930	Apoptosis Inhibitor	54135-60-3	99.70%	Associate with caspase-3 inhibition
A1931	Pyronaridine Tetraphosphate	76748-86-2	99.47%	Antimalarial agent
A1932	(-)-Huperzine A	102518-79-6	99.63%	NMDA receptor antagonist/AChE inhibitor
A1933	Carfilzomib (PR-171)	868540-17-4	99.76%	Proteasome inhibitor, epoxomicin analog
A1934	Oprozomib (ONX-0912)	935888-69-0	97.63%	Proteasome inhibitor
A1935	5-Aminovaleric acid hydrochloride	660-88-8	98.00%	used for the synthesis of polymers
A1945	BIBR 1532	321674-73-1	99.80%	Telomerase inhibitor,novel and selective
A1947	MEK162 (ARRY-162, ARRY-438162)	606143-89-9	98.17%	MEK1/2 inhibitor,potent and selective
A1952	NSC 23766	1177865-17-6	98.21%	Selective inhibitor of Rac1-GEF interaction.
A1958	Etomidate	33125-97-2	99.84%	General anesthetic with GABA modulatory and GABA-mimetic actions
A1971	Etoposide	33419-42-0	99.56%	Topo II inhibitor
A1980	SNS-032 (BMS-387032)	345627-80-7	99.49%	CDK inhibitor
A1984	Bendamustine HCl	3543-75-7	99.74%	Cytostatic agent for non-Hodgkin lymphomas
A1986	Nu 6027	220036-08-8	98.00%	ATR/CDK inhibitor, potent and selective
A1987	Ki16425	355025-24-0	99.02%	LPA receptor antagonist
A2005	Nutlin-3b	675576-97-3	98.48%	MDM2/p53 inhibitor
A2024	PD168393	194423-15-9	98.00%	EGFR inhibitor
A2025	Plerixafor (AMD3100)	110078-46-1	98.00%	CXCR4 chemokine receptor antagonist
A2033	PQ 401	196868-63-0	98.00%	IGF1R inhibitor,potent and cell-permeable
A2036	Doripenem Hydrate	364622-82-2	99.43%	Injectable antibiotic,ultra-broad spectrum
A2065	IC-87114	371242-69-2	98.00%	PI3Kδ inhibitor
A2067	PI-103	371935-74-9	98.66%	Class I PI3K, mTOR and DNA-PK inhibitor
A2080	PIK-75	372196-77-5	99.40%	Inhibitor of PI3K isoform p110α
A2097	Ifosfamide	3778-73-2	98.65%	Cytostatic agent
A2098	PRX-08066 Maleic acid	866206-55-5	98.00%	5-HT2B receptor antagonist,potent and selective
A2133	Saracatinib (AZD0530)	379231-04-6	99.86%	Src/Abl inhibitor,potent and selective
A2149	Bosutinib (SKI-606)	380843-75-4	99.78%	Potent Abl/Src kinases
A2150	Andarine	401900-40-1	99.78%	Androgen receptor agonist
A2168	Dovitinib (TKI-258, CHIR-258)	405169-16-6	99.81%	Multitargeted RTK inhibitor
A2171	Carboplatin	41575-94-4	99.50%	Antitumor agent that forms platinum-DNA adducts.
A2173	SC 144	895158-95-9	99.21%	Gp130 inhibitor
A2174	Lenvatinib (E7080)	417716-92-8	99.11%	VEGFR inhibitor
A2187	Cladribine	4291-63-8	98.01%	Apoptosis inducer in CLL cells
A2198	Genistein	446-72-0	99.24%	ER agonist
A2213	17-DMAG (Alvespimycin) HCl	467214-21-7	99.22%	Hsp90 inhibitor
A2224	Stattic	19983-44-9	99.82%	STAT3 inhibitor,small-molecule and potent
A2249	T0901317	293754-55-9	99.91%	Liver X receptor agonist,potent and selective
A2251	Tivozanib (AV-951)	475108-18-0	98.26%	VEGFR inhibitor,potent and selective
A2278	NVP-AEW541	475489-16-8	98.00%	IGF-IR inhibitor, novel, potent and selective
A2306	Ellagic acid	476-66-4	98.39%	Casein kinase 2 (CK2) inhibitor
A2307	PHA-665752	477575-56-7	98.00%	C-Met inhibitor,potent and ATP-competitive
A2308	TAK-438	1260141-27-2	98.00%	Blocker of potassium-competitive acid
A2310	SR9009	1379686-30-2	99.71%	REV-ERB-α/β Agonist
A2323	TCS 359	301305-73-7	99.26%	Potent FLT3 inhibitor
A2324	Dexamethasone (DHAP)	50-02-2	99.95%	Glucocorticoidan; anti-inflammatory
A2343	Cyclophosphamide	50-18-0	98.00%	Nitrogen mustard alkylating agent and prodrug.
A2355	Mercaptopurine (6-MP)	50-44-2	99.72%	Purine synthesis inhibitor
A2402	Floxuridine	50-91-9	99.22%	Antineoplastic antimetabolite
A2415	Acitretin	55079-83-9	99.87%	Metabolite of etretinate
A2431	Acarbose	56180-94-0	98.00%	Alpha-glucosidase inhibitor
A2436	Fluoxetine HCl	56296-78-7	99.60%	Serotonin reuptake inhibitor,selective
A2451	Epirubicin HCl	56390-09-1	98.62%	Antibiotic antitumor agent
A2456	Pamidronate Disodium	57248-88-1	98.00%	Bisphosphonate antiresorptive agent & bone resorption inhibitor
A2477	Tyrphostin AG 1296	146535-11-7	99.90%	PDGFR inhibitor,selective and ATP-competitive
A2486	Malotilate	59937-28-9	98.72%	Stimulates hepatocyte regeneration
A2487	Odanacatib (MK-0822)	603139-19-1	99.04%	Cathepsin K,potent and selective
A2489	Leucovorin Calcium	6035-45-6	98.00%	Derivative of folic acid
A2510	Ampicillin sodium	69-52-3	98.00%	β-lactam antibiotic
A2511	Carbenicillin, Disodium Salt	4800-94-6	98.00%	Inhibits the cell-wall synthesis,antibiotic
A2512	Chloramphenicol	56-75-7	99.52%	Inhibits translation(blocking peptidyl transferase)
A2513	Geneticin, G-418 Sulfate	108321-42-2	98.00%	Aminoglycosidic antibiotic
A2515	Hygromycin B	31282-04-9	98.00%	Suitable for mammalian cell selection
A2516	Kanamycin Sulfate	25389-94-0	98.00%	Water-soluble antibiotic
A2517	Tetracycline Hydrochloride	64-75-5	98.48%	Bacteriostatic antibiotics
A2521	VE-821	1232410-49-9	98.03%	ATR kinase inhibitor
A2531	Fluoroorotic Acid, Ultra Pure	703-95-7	99.62%	5-Fluoroorotic acid
A2539	X-Gal	7240-90-6	99.48%	Substrate for β-galactosidase,used in blue/white screening
A2548	Carmofur	61422-45-5	98.00%	Cytostatic derivative of fluorouracilm,antineoplatic agent
A2552	Quercetin dihydrate	6151-25-3	98.23%	PLA2 and PI 3-kinase inhibitor
A2559	Altretamine	645-05-6	99.13%	Antineoplastic agent
A2570	Leupeptin, Microbial	103476-89-7	98.00%	Inhibitor of serine and cysteine proteases
A2571	Pepstatin A	26305-03-3	98.96%	Aspartic proteinases inhibitor
A2573	AEBSF.HCl	30827-99-7	99.68%	Serine protease inhibitor
A2574	Aprotinin	9087-70-1	98.00%	Inhibitor of bovine pancreatic trypsin
A2575	Bestatin	58970-76-6	98.00%	Aminopeptidase inhibitor
A2576	E-64	66701-25-5	98.00%	Cysteine protease inhibitor,irriversible
A2577	Batimastat (BB-94)	130370-60-4	98.32%	MMP inhibitor
A2578	Clasto-Lactacystin β-lactone	154226-60-5	≥95.00%	Proteasome inhibitor
A2580	Elastase Inhibitor, SPCK	65144-34-5	98.00%	HLE inhibitor
A2583	Lactacystin (Synthetic)	133343-34-7	98.00%	Proteasome inhibitor
A2585	MG-132	133407-82-6	97.56%	Proteasome inhibitor, Cell permeable, reversible
A2586	Nafamostat Mesylate(FUT-175)	82956-11-4	99.79%	Serine protease inhibitor
A2587	PMSF	329-98-6	99.78%	Serine proteinases inhibitor, irreversible
A2588	PPACK Dihydrochloride	142036-63-3	99.10%	Thrombin inhibitor
A2597	Brivanib (BMS-540215)	649735-46-6	99.59%	VEGFR-2 inhibitor,ATP-competitive
A2600	(-)-Epigallocatechin gallate (EGCG)	989-51-5	99.12%	Antioxidant, antiangiogenic and antitumor agent
A2601	Aclacinomycin A	57576-44-0	98.00%	Topoisomerase I and II inhibitor
A2602	Calpain Inhibitor I, ALLN	110044-82-1	98.00%	Calpain I/II/ B/L inhibitor
A2603	Calpain Inhibitor II, ALLM	136632-32-1	98.00%	Calpain inhibitor
A2604	Celastrol	34157-83-0	98.67%	Antioxidant, anti-inflammatory and immunosuppressive agent
A2606	Epoxomicin	134381-21-8	97.92%	Proteasome inhibitor
A2610	Fenbendazole	43210-67-9	99.57%	For pinworm treatment in animals
A2612	MG-115	133407-86-0	98.00%	Potent reversible proteasome inhibitor
A2614	Bortezomib (PS-341)	179324-69-7	99.89%	Proteasome Inhibitor
A2623	VU 0364439	1246086-78-1	98.00%	Positive allosteric mGluR-4 modulator
A2633	Brivanib Alaninate (BMS-582664)	649735-63-7	98.00%	VEGFR2 inhibitor,ATP-competitive
A2664	VX-661	1152311-62-0	99.88%	F508del CFTR corrector
A2673	AG-1024	65678-07-1	98.00%	Selective IGF-1R inhibitor
A2678	SU11274	658084-23-2	≥95.00%	C-Met inhibitor,potent and selective
A2681	TGX-221	663619-89-4	98.91%	PI3Kβ inhibitor,potent,selective and ATP competitive
A2689	Butein	487-52-5	98.00%	Protein kinase inhibitor
A2700	10Panx	955091-53-9	99.29%	Panx-1 mimetic inhibitor
A2701	Scrambled 10Panx	1315378-72-3	98.68%	Panx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions
A2754	TG100-115	677297-51-7	98.02%	PI3Kγ/PI3Kδ inhibitor
A2782	Amonafide	69408-81-7	98.00%	DNA intercalator,Topo II inhibitor
A2806	BX-912	702674-56-4	95.55%	PDK1 inhibitor,potent and ATP-competitive
A2813	Ivermectin	70288-86-7	98.00%	NAChR/purinergic P2X4 receptor modulator
A2822	AC480 (BMS-599626)	714971-09-2	98.00%	HER1/2 inhibitor,selective and efficacious
A2838	OSI-930	728033-96-3	99.58%	Inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck
A2842	Melatonin	73-31-4	99.81%	Melatonin receptors agonist
A2845	Omeprazole	73590-58-6	97.37%	H+,K+-ATPase inhibitor
A2846	OSU-03012 (AR-12)	742112-33-0	99.43%	Potent PDK1 inhibitor
A2852	Leflunomide	75706-12-6	99.69%	AHR agonist,immunosuppressive agent
A2884	Doxazosin Mesylate	77883-43-3	99.82%	α1-adrenergic receptor antagonist
A2890	Nepafenac	78281-72-8	98.00%	COX-1 and COX-2 inhibitor
A2917	Flumazenil	78755-81-4	99.85%	Benzodiazepine antagonist
A2942	Masitinib (AB1010)	790299-79-5	99.60%	Tyrosine kinase inhibitor, potent and selective
A2949	Linifanib (ABT-869)	796967-16-3	99.62%	VEGFR/PDGFR inhibitor
A2960	Loratadine	79794-75-5	98.24%	Peripheral HH1R antagonist
A2974	Foretinib (GSK1363089)	849217-64-7	98.36%	VEGF and HGF receptor inhibitor
A2977	Cabozantinib (XL184, BMS-907351)	849217-68-1	98.60%	VEGFR2/Met/Ret/Kit/FLT//AXL inhibitor
A2986	ADL5859 HCl	850173-95-4	99.16%	δ-opioid receptor agonist,selective
A3001	PCI-32765 (Ibrutinib)	936563-96-1	99.39%	Bruton’s tyrosine kinase (BTK) inhibitor
A3002	ABT-888 (Veliparib)	912444-00-9	99.87%	Potent PARP inhibitor
A3003	MDV3100 (Enzalutamide)	915087-33-1	99.78%	Androgen receptor antagonist
A3004	Vemurafenib (PLX4032, RG7204)	918504-65-1	98.48%	BRAF kinase inhibitor
A3005	CAL-101 (Idelalisib, GS-1101)	870281-82-6	99.91%	PI3K inhibitor
A3006	GDC-0068 (RG7440)	1001264-89-6	99.06%	Pan-AKT inhibitor,highly selective
A3007	ABT-263 (Navitoclax)	923564-51-6	98.02%	Potent Bcl-2 family inhibitor, inhibits Bcl-2, Bcl-xL, and Bcl-w
A3008	Y-27632 dihydrochloride	146986-50-7;129830-38-2	99.08%	ROCK1 inhibitor
A3009	Sorafenib	284461-73-0	99.87%	Raf kinases and tyrosine kinases inhibitor
A3010	MK-2206 dihydrochloride	1032350-13-2	99.59%	Akt1/2/3 inhibitor
A3011	CHIR-99021 (CT99021)	252917-06-9	98.32%	GSK-3 inhibitor, Cell-permeable, ATP-competitive
A3012	Ruxolitinib (INCB018424)	941678-49-5	99.64%	JAK inhibitor
A3013	PD0325901	391210-10-9	99.74%	MEK inhibitor
A3014	BGJ398	872511-34-7	99.74%	FGFR inhibitor ,potent and selective
A3015	BKM120	944396-07-0	98.01%	Inhibitor of pan-Class I PI3K
A3016	PLX-4720	918505-84-7	98.70%	BRAF kinase inhibitor
A3017	Dasatinib (BMS-354825)	302962-49-8	98.09%	Src and BCR-Abl inhibitor
A3018	Trametinib (GSK1120212)	871700-17-3	98.98%	MEK1 and MEK2 inhibitor, potent and selective
A3019	AT-406 (SM-406)	1071992-99-8	98.00%	IAP inhibitor
A3021	GDC-0449 (Vismodegib)	879085-55-9	99.64%	Hedgehog antagonist,potent and selective
A3022	Pazopanib (GW-786034)	444731-52-6	98.81%	VEGFR/PDGFR/FGFR inhibitor
A3023	P005091	882257-11-6	99.67%	Ubiquitin-specific protease 7 (USP7) inhibitor
A3100	(+)-MK 801	70449-94-4	99.38%	Potent NMDA antagonist
A3104	(E)-2-Decenoic acid	334-49-6	98.00%	Fatty acid identified in royal jelly
A3108	17 alpha-propionate	19608-29-8	98.00%	Androgen antagonist
A3111	1alpha, 25-Dihydroxy VD2-D6	216244-04-1	98.00%	Deuterated form of vitamin D
A3115	24, 25-Dihydroxy VD3	40013-87-4	98.00%	Vitamin D analogue
A3118	3,3′-Diindolylmethane	1968-05-4	99.69%	Anticancer and antineoplastic agent
A3119	360A	794458-56-3	98.00%	G-quadruplex structures inhibitor
A3120	360A iodide	737763-37-0	98.56%	G-quadruplex structures inhibitor
A3122	PI4KIII beta inhibitor 3	1245319-54-3	98.00%	PI4KIII beta inhibitor
A3123	4′-Demethylepipodophyllotoxin	6559-91-7	99.32%	Anti-cancer drug
A3124	5-hydroxypyrazine-2-carboxylic acid	34604-60-9	99.15%	Metabolite of pyrazinamide (PZA)
A3125	5-Iodotubercidin	24386-93-4	98.34%	Adenosine kinase inhibitor,potent
A3126	5-R-Rivaroxaban	865479-71-6	99.49%	Factor Xa (FXa) inhibitor
A3130	A 438079	899507-36-9	98.00%	P2X7 receptor antagonist,competitive and selective
A3131	A 438079 hydrochloride	899431-18-6	99.59%	P2X7 receptor antagonist,competitive and selective
A3132	A 77-01	607737-87-1	99.50%	Potent ALK5 inhibitor
A3133	A 83-01	909910-43-6	99.24%	ALK-5 inhibitor
A3134	A-317491	475205-49-3	98.53%	P2X3 and P2X2/3 receptor antagonist
A3135	A-443654	552325-16-3	99.79%	Akt inhibitor,potent and selective
A3136	A-740003	861393-28-4	98.24%	P2X7 receptor antagonist
A3138	A-867744	1000279-69-5	98.00%	Allosteric Modulator
A3139	Abacavir	136470-78-5	99.89%	Inhibitor of HIV reverse transcriptase
A3142	Acamprosate calcium	77337-73-6	99.78%	GABA receptor agonist and modulator of glutamatergic systems
A3143	Adarotene	496868-77-0	99.24%	Apoptosis inducer/DNA damage agent
A3145	Afatinib dimaleate	850140-73-7	99.49%	EGFR inhibitor
A3146	AGI-6780	1432660-47-3	98.63%	IDH2/R140Q mutation inhibitor
A3147	AH 6809	33458-93-4	98.00%	EP and DP receptor antagonist
A3148	AIM-100	873305-35-2	98.95%	Ack1 inhibitor
A3149	AKT inhibitor VIII	612847-09-3	99.73%	Allosteric Akt kinase inhibitor
A3151	Alarelin Acetate	79561-22-1	99.88%	Synthetic GnRH agonist
A3153	Aliskiren	173334-57-1	98.95%	Direct renin inhibitor
A3155	ALK inhibitor 2	761438-38-4	98.00%	ALK inhibitor, novel and selective
A3156	Alogliptin Benzoate	850649-62-6	98.00%	DPP-4 inhibitor,selective and potent,antidiabetic drug
A3157	Alosetron	122852-42-0	98.00%	5-HT3 receptor antagonist
A3159	Alosetron Hydrochloride	122852-69-1	98.91%	5-HT3 receptor antagonist,potent and highly selective
A3162	Alvimopan	156053-89-3	99.67%	Mu-opioid receptors antagonist
A3163	Alvimopan dihydrate	170098-38-1	98.00%	μ-opioid receptor antagonist,peripherally acting
A3165	ALW-II-41-27	1186206-79-0	97.45%	Eph receptor inhibitor
A3166	AM095	1345614-59-6	98.14%	Potent LPA1 receptor antagonist
A3167	AM-095 free base	1228690-36-5	98.12%	Potent LPA1 receptor antagonist
A3169	AM679	1206880-66-1	98.00%	FLAP inhibitor
A3170	AM966	1228690-19-4	99.69%	LPA1 antagonist, oral active, high affinity, selective,
A3171	Amadacycline	389139-89-3	99.46%	Tetracycline antibiotic
A3173	AMD-070	558447-26-0	98.00%	CXCR4 antagonist,potent and selective
A3174	AMD-070 hydrochloride	880549-30-4	98.00%	CXCR4 antagonist,potent and selective
A3176	Ampalex	154235-83-3	98.54%	Ampakine and nootropic
A3177	AN-2690	174671-46-6	98.60%	Antifungal agent
A3178	AN-2728	906673-24-3	99.33%	PDE4 inhibitor,anti-inflammatory compound
A3179	Anamorelin	249921-19-5	99.68%	Ghrelin receptor agonist, synthetic, orally active
A3182	Anguizole	442666-98-0	98.00%	Inhibitor of HCV replication
A3184	AR-A014418	487021-52-3	98.34%	GSK3β inhibitor, ATP-competitive and selective
A3185	AR-C155858	496791-37-8	99.52%	MCT1 and MCT2 inhibitor
A3188	ARRY-520 R enantiomer	885060-08-2	98.00%	KSP inhibitor
A3189	AS 602801	848344-36-5	98.72%	Jun Kinase Inhibitor
A3190	ASC-J9	52328-98-0	98.00%	AR degradation enhancer,antiumor agent
A3191	Ascomycin(FK 520)	104987-12-4	98.00%	Macrolide immunosuppressant,FK-520 analog
A3192	Asenapine hydrochloride	1412458-61-7	98.00%	Atypical antipsychotic
A3193	ASP3026	1097917-15-1	99.38%	ALK inhibitor,potent and selective
A3194	AST 487	630124-46-8	99.29%	RET kinase inhibitor
A3195	Asunaprevir (BMS-650032)	630420-16-5	99.80%	NS3 protease inhibitor
A3196	AT-101	90141-22-3	98.00%	BH3-mimetic,gossypol enantiomer
A3196	AT-101	90141-22-3	98.00%	BH3-mimetic,gossypol enantiomer
A3197	AT7519 Hydrochloride	902135-91-5	99.80%	Multi-CDK inhibitor
A3197	AT7519 Hydrochloride	902135-91-5	99.80%	Multi-CDK inhibitor
A3197	AT7519 Hydrochloride	902135-91-5	99.80%	Multi-CDK inhibitor
A3197	AT7519 Hydrochloride	902135-91-5	99.80%	Multi-CDK inhibitor
A3197	AT7519 Hydrochloride	902135-91-5	99.80%	Multi-CDK inhibitor
A3198	AT7519 trifluoroacetate	1431697-85-6	98.00%	CDK/cyclin inhibitor
A3198	AT7519 trifluoroacetate	1431697-85-6	98.00%	CDK/cyclin inhibitor
A3198	AT7519 trifluoroacetate	1431697-85-6	98.00%	CDK/cyclin inhibitor
A3198	AT7519 trifluoroacetate	1431697-85-6	98.00%	CDK/cyclin inhibitor
A3199	AT7867 dihydrochloride	1431697-86-7	98.00%	Akt1 and p70S6K/PKA inhibitor
A3199	AT7867 dihydrochloride	1431697-86-7	98.00%	Akt1 and p70S6K/PKA inhibitor
A3199	AT7867 dihydrochloride	1431697-86-7	98.00%	Akt1 and p70S6K/PKA inhibitor
A3199	AT7867 dihydrochloride	1431697-86-7	98.00%	Akt1 and p70S6K/PKA inhibitor
A3201	Atrasentan hydrochloride	195733-43-8	98.00%	Endothelin receptor antagonist
A3201	Atrasentan hydrochloride	195733-43-8	98.00%	Endothelin receptor antagonist
A3201	Atrasentan hydrochloride	195733-43-8	98.00%	Endothelin receptor antagonist
A3201	Atrasentan hydrochloride	195733-43-8	98.00%	Endothelin receptor antagonist
A3202	Avermectin B1	71751-41-2	98.00%	Insecticide
A3203	Avermectin B1a	65195-55-3	90.00%	Antiparasitic agent
A3204	Avermectin B1b	65195-56-4	98.00%	mixture of avermectins